First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington

Lugano, Switzerland, June 6, 2017 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, in conjunction with the Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO), today announces Sarah A. Buckley, MD, of the University of Washington as the first recipient of the Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care.

The Conquer Cancer Foundation’s Young Investigator Award (YIA) funds physicians who are in the final years of training to aid their transition from a fellowship program to a faculty appointment. The YIA is a one-year $50,000 grant that aims to promote quality research in clinical oncology.

The inaugural recipient of this endowed YIA, Dr. Sarah A. Buckley completed an undergraduate degree in biology from Massachusetts Institute of Technology and received her medical degree from New York University. Dr. Buckley then moved to the University of Washington (UW) and is a senior fellow in hematology/oncology at UW. Dr. Buckley’s clinical interests include developing tools to improve medical decision-making for patients with aggressive myeloid malignancies and she is currently in the process of developing an acute myeloid leukemia-specific quality of life instrument. Dr. Buckley’s YIA project, which will begin this summer, is entitled Validation of a disease-specific quality of life instrument in patients with Acute Myeloid Leukemia (AML).

Established in 2016, this endowed YIA honors the life of Anna Braglia, the wife of Helsinn Group Founder and Chairman Gabriele Braglia and mother of Helsinn Group Vice Chairman and CEO Riccardo Braglia, who passed away in 2015. Helsinn endowed this award, which is part of CCF’s Grants and Award’s Program, to encourage more aspiring physicians to move into all areas of oncology by supporting them as they move from academia into research.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Dr. Sarah Buckley is an outstanding candidate for this award as her work holds the potential to radically improve our understanding of the support needed by patients with AML. In everything we do, Helsinn is committed to helping people with cancer improve their quality of life. Dr. Buckley’s work is highly complementary to this goal. We are delighted to be able to support her valuable work and wish her the best with her project.”  

Dr. Sarah A. Buckley, said: "I am honored to have been selected as the first recipient of the Anna Braglia Endowed Young Investigator Award. Patients with AML face a unique set of challenges, many of which are not captured adequately by the quality of life questionnaires that are available. The clinical focus of my group is in developing a Quality of Life questionnaire that is specific to issues faced by patients with AML, and we propose a study to see how this questionnaire works in practice.The Anna Braglia Endowed YIA, supported by Helsinn through the Conquer Cancer Foundation, will provide critical support as we progress towards the validation of a disease-specific Quality of Life instrument.”

 

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland and the U.S., a representative office in China as well as a product presence in approximately 190 countries globally. 

 

About Conquer Cancer Foundation

The Conquer Cancer Foundation (CCF) was created by the world’s foremost cancer doctors of the American Society of Clinical Oncology (ASCO) to seek dramatic advances in the prevention, treatment, and cures of all types of cancer. Toward the vision of a world free from the fear of cancer, CCF works to conquer this disease by funding breakthrough cancer research and sharing cutting-edge knowledge with patients and physicians worldwide and by improving the quality of care and access to care, enhancing the lives of all who are touched by cancer.

For more information, visit CONQUER.ORG.

 

For more information:

Helsinn Group Media Contact:

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com